

## New submissions:

<b>Empagliflozin</b>	<b>AMBER 2</b>	<ul style="list-style-type: none"> <li>For Treating Chronic Heart Failure with Reduced Ejection Fraction.</li> <li>As per NICE TA773.</li> <li>Treatment of Heart Failure with PRESERVED ejection fraction classified as GREY no formal assessment.</li> </ul>
<b>Dapagliflozin</b>	<b>AMBER 3</b>	<ul style="list-style-type: none"> <li>As per <a href="#">NICE TA775</a> guideline.</li> <li>As an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs). <ul style="list-style-type: none"> <li>For people with an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m<sup>2</sup> to 75 ml/min/1.73 m<sup>2</sup> at the start of treatment and: <ul style="list-style-type: none"> <li>-have type 2 diabetes or</li> <li>-have a urine albumin-to-creatinine ratio (uACR) of 22.6 mg/mmol or more.</li> </ul> </li> </ul> </li> </ul>
<b>Myopridin</b>	<b>GREY</b>	<ul style="list-style-type: none"> <li>For the treatment of muscle spasms, lumbar pain, torticollis and general muscle pain in adults.</li> <li>Insufficient evidence currently available to support its use locally.</li> </ul>
<b>Rivaroxaban (Xarelto®) (tablets: 15mg, 20mg, and 1mg/ml oral suspension)</b>	<b>AMBER 2</b>	<ul style="list-style-type: none"> <li>For the treatment and prevention of recurrence of venous thromboembolism (VTE) in children.</li> <li>Courses of 3 months or less classified as <b>RED</b>.</li> <li>Two different pack sizes of oral suspension are available, with different sized syringes depending on body weight.</li> </ul>
<b>Micronised Vaginal Progesterone (Utrogestan®)</b>	<b>Deferred to DTC to consider RED</b>	<ul style="list-style-type: none"> <li>For women with an intrauterine pregnancy confirmed by a scan, if they have vaginal bleeding and have previously had a miscarriage.</li> <li>If a fetal heartbeat is confirmed, continue progesterone until 16 completed weeks of pregnancy.</li> </ul>

## News from the APC - updated/new documents:

[Hypothyroidism in Pregnancy Primary Care Guidance](#) (new) - Guidance on the different service pathways for NUH and SFH. Patients under NUH are now managed within primary care.

[Acute sinusitis](#) (update) - Self care/patient information links. Corticosteroid nasal spray use.

[Chronic bacterial sinusitis](#) (update) - Self care/patient information links. Corticosteroid nasal spray use.

[Dental abscess](#) (update) - Definitive and appropriate treatment can only be given by a dentist. Medication will not eliminate the source of infection. Clindamycin removed as antibiotic option.

[Dermatophyte infection](#) (update) - Inclusion criteria for sending adult nail specimens to the lab. Information regarding the risk of hepatotoxicity and the need for baseline liver function testing.

[Hidradenitis suppurative](#) (new) - Also known as acne inversa. Includes general measures for patients, general and medical management, and indications for referral.

[UTI](#) (update) - Updated antimicrobial UTI guidelines include: Complicated UTI, Lower UTI, Quick Reference UTI Guide, Acute Pyelonephritis and UTI in Pregnancy.

[Emollient formulary](#) (update) - First and second line options for severely dry skin changed, emulsifying ointment no longer first choice. Emulsifying ointment and 50:50 ointment must be prescribed by brand in primary care.

[Domperidone for lactation stimulation](#) (updated letter and new prescribing info sheet)

[Alternatives to using an unlicensed "specials" database](#) (update) - DOAC: detail on crushing tablets (licensed for edoxaban, rivaroxaban & apixaban). SGLT2 inhibitors: no licensed liquids, added advice on crushing tablets from regional MI centre (off licence). Atorvastatin: licensed liquid is non-formulary (significant alcohol content and expensive), use chewable tablets instead.

[End of Life guideline](#) (update)

[Male Lower Urinary Tract Symptoms \(LUTS\)](#) (update)

## Horizon scanning, formulary amendments and traffic light changes

### Horizon scanning

#### Added to formulary as **GREY** non formulary:

Liothyronine hard capsules (Roma Pharmaceuticals) in line with other liothyronine preparations.  
Sereflo Ciphaler DPI (fluticasone / salmeterol) – new initiation of fluticasone/salmeterol not recommended.

#### New formulations:

Calcipotriol 50mcg & betamethasone dipropionate 0.5mg cream (Wynzora) – added as **GREEN** (gel and ointment already **GREEN**).  
Cimetidine 200mg/5ml oral solution (Tagamet<sup>®</sup> syrup) – already on formulary but add note that it is more cost effective than prescribing SF oral solution.

### Formulary Amendments

#### Minor amendments:

Estradiol pessaries - Vagirux<sup>®</sup> brand now preferred to Vagifem<sup>®</sup> (cost effective and less plastic waste).  
Alprostadil - Viridal Duo<sup>®</sup> **GREY** (had been temporarily **AMBER 2** due to Caverject<sup>®</sup> shortage, now resolved).  
Clonidine - 100microgram tablet added to formulary (25mcg already on formulary).

#### Oral Nutritional Supplements:

Slo Milkshakes – make this and other pre-thickened products **AMBER 2** on dietitian recommendation (currently unclassified).  
Aymes ActaGain 2.4 Complete Maxi – Banana flavour added.  
Aymes ActaGain 600 – **AMBER 2** dietitian recommendation only, low volume alternative to ActaGain 2.4.  
Nualtra Altraplen Energy – **AMBER 2** dietitian recommendation only.  
Aymes Shake Fibre – **AMBER 2** dietitian recommendation only.  
Aymes ActaCal Crème - **AMBER 2** dietitian recommendation only.

#### Other formulary amendments:

Sharps bins – **GREEN**, information added about prescribing and waste collection.  
Ethyl chloride BP (e.g. Cryogestic<sup>®</sup> spray) – **GREEN**, but cannot be prescribed on FP10.  
Combodart<sup>®</sup> brand of dutasteride / tamsulosin capsules - **GREY** non-formulary (not cost-effective).  
Generic dutasteride / tamsulosin capsules - **AMBER 3**  
Atorvastatin oral solution – **GREY** due to significant alcohol content and expense (licensed chewable tablets available as alternative).

### **APC webinars - new**

A pre-recorded APC update webinar is now available to view on our [YouTube channel](#)

### **Current work in development– see [APC work programme](#) for further details**

- Type 2 diabetes guideline (update)
- Sick day rules and SGLT2s (new)
- Growth Hormone SCP (update)
- Anticoagulants for NVAF Guideline (update)
- Bariatric surgery – post op monitoring and medication (update)
- Testosterone for women prescribing Information sheet
- Aminosalicylates in IBD (update)
- Antimicrobial guidelines (update)
- Home oxygen pathway for cluster headache (update)
- Lower carbon salbutamol inhalers – position statement (new)
- Steroid emergency card – patient information (new)
- Transgender collaborative care protocol and prescribing information sheets (new)

The work of the NAPC is supported and managed by the interface team. They can be contacted via [nccg.nottsapc@nhs.net](mailto:nccg.nottsapc@nhs.net)